Medium-term course and outcome of schizophrenia depicted by the sixth-month subtype after an acute episode

Liu, Chen-Chung; Chen, Chun-Houh; Shiu, Shang-Ying; Hua, Mau‐Sun; Chen, Chen-Hsin; Hwang, Tzung‐Jeng; Hsieh, Ming H.; Liu, Shi-Kai; Chen, Wei-Jen

doi:10.1016/j.jfma.2011.01.007

Cited by 5 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Acute agitation is common in the course of schizophrenia and may be accompanied by destructive and/or violent behaviors. 2,3 Rapid tranquilization with preferred intramuscular (IM) formulations of psychotropic medications is usually warranted under such circumstances.…”

Section: Introductionmentioning

confidence: 99%

Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial

Huang

Hwang

Chen

et al. 2015

Journal of the Formosan Medical Association

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial

Huang

Hwang

Chen

et al. 2015

Journal of the Formosan Medical Association

Self Cite

View full text Add to dashboard Cite

show abstract

“…A further two studies included functional outcome as an endpoint measure but did not use a specific instrument to assess this. Instead, Novick et al 33 assessed the level of social functioning by quantifying the number of activities performed with friends/social groups in the preceding 4 weeks and Liu et al 31 classified patients as either high or low functioning based on assessment of several factors including personal relationships, family life, achievement and time planning. In the included articles, functional outcome was typically either a secondary or exploratory/ancillary endpoint.…”

Section: Resultsmentioning

confidence: 99%

Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia

Hadzi Boskovic,

Smith-Palmer,

Pöhlmann

et al. 2024

PROM

View full text Add to dashboard Cite

“…These patients stopped receiving treatment as a result, which caused their psychotic symptoms to reappear. [4][5][6] Developed in the 1970s and 1980s, long-acting injectable antipsychotics, or LAIs, were intended to increase treatment adherence for mental health conditions. Despite this, there were not enough thorough research carried out at the time to adequately prove the efficacy of LAIs.…”

Section: Introductionmentioning

confidence: 99%

Optimal values exploration for responsiveness rates in stable and unstable schizophrenic patients

Maher A J. Alasasleh,

Raafat Hani Aburumman,

Arafat Khalaf Alzoubi

et al. 2024

World J. Bio. Pharm. Health Sci.

View full text Add to dashboard Cite

Background: Schizophrenia leads to multifunctional disability, characterized by cognitive and social impairments, everyday skill and self-assessment difficulties, and negative symptoms. Long-term clinical stability, often achieved with antipsychotics, improves everyday functioning. Aim: The goal is to determine to determine the efficacy of different antipsychotic classes (%Prob of APDs' Resp) and adherence rates, as measured by the Behavioural Adherence Rating Scale (BARS). Methods: The study focuses on schizophrenia-spectrum disorders in adults and elderly psychiatric patients, using established diagnostic systems. The observational and retrospective study will be conducted at the Princess Aisha Bint Al Hussein Medical Centre from January 2021 to January 2023. The study will use positive and negative symptom domains to measure initial severity and assess ideal values for antipsychotic drugs. A Chi Square test will be used to analyze distribution rates and odds ratios. The study will use SPSS version 25 with a 5% significance level. Results: The binary logistic regression model was created using patient adherence patterns evaluated using BARS. The model aimed to predict positive responsiveness (Δ PANSS≥20%) and negative responsiveness (Δ PANSS<20%) using patient data. The model accurately identified 94.4% of cases, with a chi-square value of 4.412 and a p-value of 0.818. BARS testing revealed a probable range of APDs' reaction from 64.4% to 88.2%, with individuals determining this range. The study suggests that the specific range may be different depending on the Cox & Snell R2 or Nagelkerke R2 procedures used, but all factors should be considered. The model's accuracy is significant, and the findings suggest that individuals are responsible for determining this range. Conclusion: The study reveals that psychotic individuals require 68.5% adherence for optimal responsiveness. Adding LAIAP to oral APDs enhances responsiveness.

show abstract

Medium-term course and outcome of schizophrenia depicted by the sixth-month subtype after an acute episode

Cited by 5 publications

References 44 publications

Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial

Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial

Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia

Optimal values exploration for responsiveness rates in stable and unstable schizophrenic patients

Contact Info

Product

Resources

About